Background Urogenital atrophy (UA) is a common treatment-limiting side effect of endocrine therapies. Topical estrogen is effective but systemic absorption may counter aromatase inhibitor efficacy. Numerous complementary approaches are marketed for use in UA without rigorous testing of their estrogenicity. https://www.diegojavierfares.com/best-flash-Umcka-Cold-Flu-4-OZSyrupBerry-amazing-save/